Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Druggable Targets of Squamous Cell Lung Cancer

  • Kim, Cheol Hyeon (Division of Pulmonology, Department of Internal Medicine, Korea Cancer Center Hospital)
  • Received : 2013.07.29
  • Accepted : 2013.08.12
  • Published : 2013.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Knowledge of molecular pathogenesis of non-small cell lung cancer has increased remarkably and changed the principles of treatment, especially during the past decade. These advancements have been limited mainly to adenocarcinoma of the lung. Recently, genetic alterations in squamous cell lung cancer (SQCLC) have been detailed and positive results of clinical trials using agents targeting these changes have indicated the potential for improved treatment outcomes for SQCLC.

Keywords

References

  1. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175-80. https://doi.org/10.1016/S1470-2045(10)70087-5
  2. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25. https://doi.org/10.1038/nature11404
  3. Drilon A, Rekhtman N, Ladanyi M, Paik P. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol 2012;13:e418-26. https://doi.org/10.1016/S1470-2045(12)70291-7
  4. Perez-Moreno P, Brambilla E, Thomas R, Soria JC. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 2012;18:2443-51. https://doi.org/10.1158/1078-0432.CCR-11-2370
  5. Semrad TJ, Mack PC. Fibroblast growth factor signaling in non-small-cell lung cancer. Clin Lung Cancer 2012;13:90-5. https://doi.org/10.1016/j.cllc.2011.08.001
  6. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM,et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2:62ra93.
  7. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011;6:e20351. https://doi.org/10.1371/journal.pone.0020351
  8. Ford CE, Lau SK, Zhu CQ, Andersson T, Tsao MS, Vogel WF. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br J Cancer 2007;96:808-14. https://doi.org/10.1038/sj.bjc.6603614
  9. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011;1:78-89. https://doi.org/10.1158/2159-8274.CD-11-0005
  10. Heist RS, Sequist LV, Engelman JA. Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol 2012;7:924-33. https://doi.org/10.1097/JTO.0b013e31824cc334
  11. Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, Blumenschein GR, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating Met- MAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 2011;29(Suppl):7505. https://doi.org/10.1200/jco.2011.29.15_suppl.7505
  12. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009;41:1238-42. https://doi.org/10.1038/ng.465
  13. Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010;28:49-55. https://doi.org/10.1200/JCO.2009.22.9427
  14. Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011;22:1374-81. https://doi.org/10.1093/annonc/mdq618
  15. Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H, et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable nonsmall- cell lung cancer. J Clin Oncol 2010;28:3131-7. https://doi.org/10.1200/JCO.2009.23.9749

Cited by

  1. Prognostic Value of MAC30 Expression in Human Pure Squamous Cell Carcinomas of the Lung vol.17, pp.5, 2013, https://doi.org/10.7314/apjcp.2016.17.5.2705